Lupus skin drug trial halted early – what we know
NCT ID NCT05629208
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental oral drug called edecesertib (GS-5718) in 20 people with cutaneous lupus erythematosus, a condition where lupus affects the skin. The goal was to see if the drug could reduce skin disease activity and improve symptoms. However, the trial was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Edecesertib (also called GS-5718), an oral tablet
What this could lead to
If successful, this could point toward a new treatment option for people with cutaneous lupus erythematosus, a skin condition caused by lupus.
What could go wrong
This was a very small, early-phase study that was terminated early, so we don't know if the drug works or is safe. The results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ARENSIA Exploratory Medicine, LLC
Phoenix, Arizona, 85015, United States
-
Center for Dermatology Clinical Research Inc.
Fremont, California, 94538, United States
-
Clinical Investigations of Texas
Plano, Texas, 75075, United States
-
Clinical Research of West Florida, Inc.
Clearwater, Florida, 33765, United States
-
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46250, United States
-
Dept. of Dermatology, Hospital of the University of Pennsylvania, Perelman Center for Advanced Medicine (PCAM)
Philadelphia, Pennsylvania, 19104, United States
-
Emory University School of Medicine
Atlanta, Georgia, 30303, United States
-
Gulf Bank Medical Center
Houston, Texas, 77037, United States
-
HMD Research LLC
Orlando, Florida, 32819, United States
-
Hospital General de Granollers
Granollers, 08402, Spain
-
Hospital Universitario de Navarra
Pamplona, 31008, Spain
-
Reliant Medical Research
Miami, Florida, 33165, United States
-
Universitatsklinikum Freiburg Klinik fur Dermatologie und Venerologie
Freiburg im Breisgau, 79104, Germany
-
University of Colorado, Barbara Davis Center, Center for Clinical Research
Aurora, Colorado, 80045, United States
-
Universitätsklinikum Carl Gustav Carus Klinik und Poliklinik für Dermatologie
Dresden, 01307, Germany
-
Universitätsklinikum Leipzig AöR Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie Klinische Forschungseinheit (KFE) - Haus 10
Leipzig, 04103, Germany
-
Yale Center for Clinical Investigation (YCCI)
New Haven, Connecticut, 06510, United States